Complaints Outcomes

Search

Search Results

Search Again
Phalore, Jagbir (Aug 3, 2018)

The Inquiry Committee has reviewed information that indicates Mr. Phalore’s practice is now meeting practice standards. Therefore, after reviewing and reconsidering this case, the Inquiry Committee determined that the current limits and conditions on Mr. Phalore’s practice are no longer necessary.

Limits and conditions on Mr. Phalore’s practice have now been removed.


November 29, 2016
(August 3, 2018 – Limits and conditions removed)

Pursuant to s. 35(4) of the Health Professions Act, the Inquiry Committee has determined that the limits and conditions imposed on the practice of pharmacy by Mr. Jagbir Phalore on May 16, 2016 are no longer necessary.

Pursuant to s. 36(1) of the Health Professions Act, the Inquiry Committee has reached an agreement with Mr. Phalore, effective November 29, 2016, where he undertaken to always follow certain steps in his pharmacy practice, and to disclose these undertakings to employers and potential employers. He will also be restricted from acting the following roles in his practice:

  1. Be an owner or manager of a pharmacy;
  2. Be a director of a corporation that owns a pharmacy; and
  3. Act as a preceptor.

After two years from November 29, 2016, Mr. Phalore may request that the Inquiry Committee remove the above limits and conditions, subject to a further review of the case by the Inquiry Committee.


May 16, 2016
(November 29, 2016 - Limits and conditions updated) 

The Inquiry Committee, pursuant to Section 35(1) of the Health Professions Act, R.S.B.C. 1996, c. 183, for the purposes of public protection, has imposed limits and conditions on the practice of registrant Jagbir Phalore, effective immediately, pending a Practice Audit of his pharmacy practice. Until further notice, Mr. Phalore has the following limits and conditions on his practice:

  1. At all times, he must work under the direct supervision of a BC licensed pharmacist in good standing, similar to a student/preceptor situation; 

  2. He will be restricted from acting in the following roles in his practice: :

    1. Be an owner or manager of a pharmacy;
    2. Be a director of a corporation that owns a pharmacy; and
    3. Act as a preceptor.

     

  3. Prior to the commencement of new employment at any pharmacy, he will inform every manager and employer of the pharmacy in which he gains employment of the limits and conditions on his license pursuant to this order, and will ensure that the pharmacy manager and employer submits a written statement to the College declaring their awareness of the limits and conditions and how the limits and conditions will be accommodated in the pharmacy.

The Inquiry Committee considered this action necessary to protect the public, due to its concerns regarding the registrant’s ability to practice safely and to comply with legislative requirements and practice standards in a hospital and/or community pharmacy setting.

Pharmacist Registrant 38 (Aug 2, 2018)

The Inquiry Committee, pursuant to s. 32.2(4)(b)(i) of the Health Professions Act, has reached an agreement with the pharmacist registrant to place limits and conditions on his pharmacy practice, pending further disposition of the Inquiry Committee. The pharmacist registrant will be limited to working in a pharmacy for no more than four hours a day and must work with another pharmacy staff member at all times. The Inquiry Committee considers this agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to s. 39.3(4) of the Health Professions Act.

Pharmacy Technician Registrant 2 (Jul 27, 2018)

The Inquiry Committee, pursuant to Section 32.2 of the Health Professions Act, has reached an agreement with pharmacy technician registrant to suspend her registration as a pharmacy technician for an indefinite period pending further decision of the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act

Zanotto , Aaron Ariel Glaser (Jul 20, 2018)

Pursuant to section 35(1)(b) of the Health Professions Act, effective July 20, 2018, the Inquiry Committee has directed an extraordinary suspension of the registration of registrant Aaron Ariel Glaser Zanotto pending completion of an investigation. The registrant will not be able to practice pharmacy in the province of British Columbia while his registration is suspended. The Inquiry Committee considered the extraordinary suspension necessary to protect the public.

While practicing as a pharmacist, the registrant allegedly made online postings, the contents of which may be regarded as reflecting harm and a risk to the public.

Note: Suspensions ordered by the Inquiry Committee under section 35(1)(b) of the Health Professions Act are made to protect the public during an investigation or pending a hearing of the Discipline Committee. Orders made under this section relate to matters which are and remain unproven unless admitted by a registrant or determined by the Discipline Committee.

Pharmacist Registrant 34 (Jul 4, 2018)

The Inquiry Committee has reinstated Pharmacist Registrant’s registration which had previously be suspended for an indefinite period on February 10, 2018.  Pursuant to Section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings.  The undertakings include, but are not limited to:

  1. The Registrant will comply with any and all recommendations and treatment prescribed or directed by his physician; and
  2. The Registrant will follow a regular monitoring program for his medical condition for a two year period. 

The Agreement will remain in place until such time as the Registrant’s physician states otherwise. The name of the Registrant has been withheld in accordance with section 39.3(4) and (6) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant. The Inquiry Committee is satisfied that the undertakings will protect the public. 


Feb 10, 2018
(July 4, 2018 - Registration reinstated)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to suspend his registration as a pharmacist for an indefinite period pending further decision of the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act

Pharmacist Registrant 37 (Jun 25, 2018)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to suspend his registration as a pharmacist for an indefinite period pending further decision of the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.

Pharmacist Registrant 36 (Jun 10, 2018)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to suspend her registration as a pharmacist for an indefinite period pending further decision of the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act

Pharmacist Registrant 21 (Jun 10, 2018)

The Inquiry Committee, pursuant to section 36(1) of the Health Professions Act, has reached a new Agreement with the pharmacist registrant to amend certain terms in his Agreement of May 1, 2017. The pharmacist registrant is now no longer subject to medical monitoring. All other limits and conditions will remain as part of the new Agreement for a minimum of six months, after which the registrant’s medical condition may be reassessed. The registrant has also agreed to begin a gradual return to work. The name of the registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition.


May 11, 2017
(June 10, 2018 - Limits and Conditions Updated)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on July 27, 2016. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. Strictly adhering to his routine medical monitoring program with the institution currently involved in his care and remaining on the monitoring program for a period of 12 months;

  2. Informing all managers and employers with whom Registrant gains employment of Registrant’s medical condition and the limits and conditions on Registrant’s registration pursuant to the agreement;

  3. Ensuring that all managers and employers with whom Registrant gains employment submits a written statement to the College declaring their awareness of Registrant’s medical condition and the agreement, and how they will accommodate and supervise Registrant working in pharmacy;

  4. Registrant will not work alone in a pharmacy setting, meaning that Registrant must never be the sole pharmacist in attendance at any time and that there must be another pharmacist or pharmacy assistant or pharmacy staff working with Registrant at all times;

  5. Registrant will not have access to narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  6. Registrant will not be involved in any way with ordering supplies of narcotic medications;

  7. The Registrant will not process and/or otherwise prepare any prescriptions that require access to the narcotic safe. In dispensing such prescriptions, the Registrant will only be involved in the intake, final check and pharmacist/patient counseling in accordance with the HPA Bylaws;

  8. The Registrant will be restricted from acting in the following roles in Registrant’s practice:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

     

  9. The Registrant will notify the College, in writing or via e-mail, of:

    1. all changes in his places of employment as a pharmacist
    2. all changes in residential address and phone number; and
    3. all changes in medical provider.

The Agreement will remain in place for a minimum of 12 months from the date of execution of the Agreement, following which the Registrant may submit information or documentation, including independent medical assessments, to support removing any or all of the above limits and conditions. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


July 27, 2016
(May 1, 2017 – Registration Reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to suspend his registration as a pharmacist, effective July 27, 2016. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld, pursuant to s. 39.3(4) of the Health Professions Act.


February 27, 2015
(July 27, 2016 – Registration Suspended)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on July 23, 2014. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. Strictly adhering to his routine medical monitoring program with the institution currently involved in his care and remaining on the monitoring program for a period of 3 years;

  2. Informing all managers and employers with whom Registrant gains employment of Registrant’s medical condition and the limits and conditions on Registrant’s registration pursuant to the agreement;

  3. Ensuring that all managers and employers with whom Registrant gains employment submits a written statement to the College declaring their awareness of Registrant’s medical condition and the agreement, and how they will accommodate and supervise Registrant working in pharmacy;

  4. Registrant will not work alone in a pharmacy setting, meaning that Registrant must never be the sole pharmacist in attendance at any time and that there must be another pharmacist or pharmacy assistant or pharmacy staff working with Registrant at all times;

  5. Registrant will not have access to narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  6. Registrant will not be involved in any way with ordering supplies of narcotic medications;

  7. The Registrant will not process and/or otherwise prepare any prescriptions that require access to the narcotic safe. In dispensing such prescriptions, the Registrant will only be involved in the intake, final check and pharmacist/patient counseling in accordance with the HPA Bylaws;

  8. The Registrant will be restricted from acting in the following roles in Registrant’s practice:

    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

  9. The Registrant will notify the College, in writing or via e-mail, of:

    1. all changes in his places of employment as a pharmacist
    2. all changes in residential address and phone number; and
    3. all changes in medical provider.

The agreement will remain in place for a minimum of three years from the date of execution of the Agreement, following which the Registrant will be assessed by a physician to determine whether or not continuation of monitoring is necessary. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


JULY 23, 2014
(FEBRUARY 27, 2015 – REGISTRATION REINSTATED)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to suspend his registration as a pharmacist, effective July 23, 2014. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld, pursuant to s. 39.3(4) of the Health Professions Act.

Pharmacist Registrant 23 (May 26, 2018)

The Inquiry Committee, pursuant to section 36(1) of the Health Professions Act, has reached a new Agreement with the pharmacist registrant to amend certain terms in his Agreement of March 6, 2017. The pharmacist registrant is now no longer subject to limits and conditions relating to working alone and the handling, counting, and dispensing of narcotic, controlled, opioid and sedative drugs. All other limits and conditions will remain as part of the new Agreement.


March 6, 2017
(May 26, 2018 - Limits and conditions updated)

The Inquiry Committee, pursuant to Section 36 of the Health Profession Act, has reached a new revised agreement with the pharmacist registrant, whereby the registrant consented to undertakings that include, but are not limited to:

  1. Strictly adhering to registrant’s routine medical monitoring program with the institution currently involved in registrant’s care and remaining on the monitoring program for a period of 5 years;

  2. Informing all managers and employers with whom registrant gains employment of registrant’s medical condition and the limits and conditions on registrant’s registration pursuant to the Agreement;

  3. Registrant will not work alone in a pharmacy setting, meaning that registrant must never be the sole pharmacist in attendance at any time and that there must be another pharmacist or pharmacy assistant or pharmacy staff working with registrant at all times;

  4. Registrant will not have access to narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  5. Registrant will not be involved in any way with ordering supplies of narcotic medications;

  6. The registrant will not physically prepare prescriptions for narcotic, controlled, opioid and sedative drugs (including but not limited to barbiturates, benzodiazepines and “z” drugs such as zopiclone, zaleplon, zolpidem and the like). In dispensing such prescriptions, the registrant will only be involved in the intake, data entry, computer processing, final check and pharmacist/patient counseling in accordance with the Health Professions Act, Bylaws; for a period of one (1) year, after which this term will be reassessed.

  7. The registrant will not dispose or deal with wastage or breakage of or otherwise handle any narcotic, controlled, opioid and sedative drugs (including but not limited to barbiturates, benzodiazepines and “z” drugs such as zopiclone, zaleplon, zolpidem and the like); for a period of one (1) year, after which this term will be reassessed.

  8. The registrant will not be restricted from acting in the role in registrant’s practice as pharmacy manager or director but he will be restricted from acting in the role in registrant’s practice as a preceptor;

  9. The registrant will notify the College, in writing or via e-mail, of:

    1. all changes in his places of employment as a pharmacist
    2. all changes in residential address and phone number; and
    3. all changes in medical provider.

This agreement will remain in place for a minimum of four years from March 6, 2017, following which the registrant will be assessed by a physician to determine whether or not continuation of monitoring is necessary. The name of the registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


JUNE 23, 2016
(MARCH 6, 2017 – LIMITS AND CONDITIONS UPDATED)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on December 18, 2015. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. Strictly adhering to Registrant’s routine medical monitoring program with the institution currently involved in Registrant’s care and remaining on the monitoring program for a period of 5 years;

  2. Informing all managers and employers with whom Registrant gains employment of Registrant’s medical condition and the limits and conditions on Registrant’s registration pursuant to the agreement;

  3. Ensuring that all managers and employers with whom Registrant gains employment submits a written statement to the College declaring their awareness of Registrant’s medical condition and the agreement, and how they will accommodate and supervise Registrant working in pharmacy;

  4. Registrant will not work alone in a pharmacy setting, meaning that Registrant must never be the sole pharmacist in attendance at any time and that there must be another pharmacist or pharmacy assistant or pharmacy staff working with Registrant at all times;

  5. Registrant will not have access to narcotic-safe or physically process and/or otherwise prepare any prescriptions that require access to the narcotic safe;

  6. Registrant will not be involved in any way with ordering supplies of narcotic medications;

  7. For one (1) year, Registrant will not physically prepare prescriptions for narcotic, controlled, opioid and sedative drugs (including but not limited to barbiturates, benzodiazepines and “z” drugs such as zopiclone, zaleplon, zolpidem and the like). In dispensing such prescriptions, the Registrant will only be involved in the intake, data entry, computer processing, final check and pharmacist/patient counseling in accordance with the Health Professions Act, Bylaws; after which this term will be reassessed.

  8. For one (1) year, Registrant will document the steps taken for dispensing narcotic and controlled drugs and ensure that Registrant’s peer co-signs the document to show compliance with the restrictions set forth in item 7; after which this term will be reassessed.

  9. For one (1) year, Registrant will not dispose or deal with wastage or breakage of or otherwise handle any narcotic, controlled, opioid and sedative drugs (including but not limited to barbiturates, benzodiazepines and “z” drugs such as zopiclone, zaleplon, zolpidem and the like); after which this term will be reassessed.

  10. The Registrant will be restricted from acting in the following roles in Registrant’s practice:
    1. an owner or manager of a pharmacy;
    2. a director of a corporation that owns a pharmacy; and
    3. a preceptor;

     

  11. The Registrant will notify the College, in writing or via e-mail, of:
    1. all changes in his places of employment as a pharmacist
    2. all changes in residential address and phone number; and
    3. all changes in medical provider.

The agreement will remain in place for a minimum of five years from the date of execution of the Agreement, following which the Registrant will be assessed by a physician to determine whether or not continuation of monitoring is necessary. The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


DECEMBER 18, 2015
(JUNE 23, 2016 – REGISTRATION REINSTATED)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to suspend his registration as a pharmacist effective December 18, 2015. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The registrant's name has been withheld, pursuant to 39.3(4) of the Health Professions Act.

Pharmacist Registrant 16 (May 24, 2018)

Pharmacist registrant 16 has satisfied the terms of an agreement reached with the Inquiry Committee dated May 24, 2013.  Limits and conditions on the pharmacist registrant’s registration as a pharmacist have now been removed. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.


May 27, 2013
(May 24, 2018 – Limits and conditions removed)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on April 17, 2013. Pursuant to Section 36 of the Health Professions Act, the Inquiry Committee has reached an agreement with pharmacist registrant in which she was asked to consent to certain undertakings. This agreement remains in effect until May 24, 2018. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act


April 27, 2013
(MAY 27, 2013 – REGISTRATION REINSTATED)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to suspend her registration as a pharmacist for an indefinite period pending further disposition by the Inquiry Committee. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.

Pages